<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="122650">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01845272</url>
  </required_header>
  <id_info>
    <org_study_id>CJ_CCA_101</org_study_id>
    <nct_id>NCT01845272</nct_id>
  </id_info>
  <brief_title>Pharmacokinetic Interactions of Candesartan Cilexetil and Amlodipine Besylate</brief_title>
  <acronym>CCA</acronym>
  <official_title>Open-label, Randomized, Single-dose, Crossover Study to Evaluate the Pharmacokinetic Interactions of Candesartan Cilexetil and Amlodipine Besylate in Healthy Male Volunteers.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>CJ HealthCare Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>CJ HealthCare Corporation</source>
  <oversight_info>
    <authority>Korea: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is designated to evaluate the pharmacokinetic interactions of candesartan
      cilexetil and amlodipine besylate in healthy male volunteers.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>April 2013</start_date>
  <completion_date type="Anticipated">August 2013</completion_date>
  <primary_completion_date type="Anticipated">July 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science</study_design>
  <primary_outcome>
    <measure>Assessment of the drug-drug interactions of candesartan and amlodipine</measure>
    <time_frame>10 days</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Part 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>single administration : candesartan cilexetil 32mg, qd, 10days(oral).
combination administration : candesartan cilexetil 32mg and amlodipine 10mg, qd, 10days(oral).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>single administration : amlodipine 10mg, qd, 10days(oral).
combination administration : candesartan cilexetil 32mg and amlodipine 10mg, qd, 10days(oral).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>candesartan cilexetil 32mg, amlodipine 10mg</intervention_name>
    <description>Treatment A (candesartan 10 days), at least 4 days wash-out, Treatment B (candesartan + amlodipine 10 days, 2-period, 2-treatment crossover</description>
    <arm_group_label>Part 1</arm_group_label>
    <arm_group_label>Part 2</arm_group_label>
    <other_name>atacand 32mg, norvasc 10mg</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>candesartan cilexetil 32mg, amlodipine 10mg</intervention_name>
    <description>Treatment A (amlodipine 10 days), at least 4 days wash-out, Treatment B (candesartan + amlodipine 10 days, 2-period, 2-treatment crossover</description>
    <arm_group_label>Part 1</arm_group_label>
    <arm_group_label>Part 2</arm_group_label>
    <other_name>atacand 32mg, norvasc 10mg</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male volunteers in the age between 20 and 55 years old(inclusive)

          -  Body mass index (BMI) in the range of 18.5 to 27 kg/m2(inclusive)

          -  Available for the entire study period

          -  Understand the requirements of the study and voluntarily consent to participate in
             the study

        Exclusion Criteria:

          -  Subjects with a history of gastrointestinal diseases which might significantly change
             ADME of medicines

          -  Systolic blood pressure outside the range of 100 to 150 mmHg or diastolic blood
             pressure outside the range of 60 to 1000 mmHg for male subjects. when screening
             period

          -  Subject with symptoms of acute disease within 14days prior to study medication dosing

          -  Subjects with a history of clinically significant allergies

          -  Subjects with a hereditary problems, for example, galactose intolerance, Lapp lactase
             deficiency or glucose-galactose malabsorption

          -  Subjects whose clinical laboratory test values are outside the accepted normal
             range(Especially,AST or ALT &gt;1.5 times to normal range or total bilirubin &gt; 1.5times
             to normal range)

          -  History of drug abuse

          -  History of caffeine, alcohol, smoking abuse

               -  caffeine(coffee,tea,coke) or grapefruit juice &gt; 4cups/day

               -  smoking &gt; 20 cigarettes/day

               -  alcohol &gt; 140g/week

          -  Positive test results for HBs Ab, HCV Ab, Syphilis regain test

          -  Participation in any clinical investigation within 30days prior to study medication
             dosing

          -  Subjects with whole blood donation within 60days, component blood donation within
             30days and blood transfusion within 30days prior to study medication dosing

          -  Subjects considered as unsuitable based on medical judgement by investigators
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jae-wook Ko, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Samsung Medical Center</affiliation>
  </overall_official>
  <verification_date>April 2013</verification_date>
  <lastchanged_date>April 30, 2013</lastchanged_date>
  <firstreceived_date>April 23, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Amlodipine</mesh_term>
    <mesh_term>Candesartan cilexetil</mesh_term>
    <mesh_term>Candesartan</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
